Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Tryponosoma cruzi infection model

被引：41

作者：

Cazorla, Silvia I. ^{[1
,2
,3
]}

Frank, Fernanda M. ^{[1
,2
]}

Becker, Pablo D. ^{[3
]}

Corral, Ricardo S. ^{[4
]}

Guzman, Carlos A. ^{[3
]}

Malchiodi, Emilio L. ^{[1
,2
]}

机构：

[1] Univ Buenos Aires, Catedra Immunol & Inst Estudios Inmunidad Humoral, IDEHU, CONICET,Fac Farm & Bioquim, RA-1113 Buenos Aires, DF, Argentina

[2] Univ Buenos Aires, Dept Microbiol Parasitol & Immunol, Fac Med, RA-1113 Buenos Aires, DF, Argentina

[3] Helmholtz Ctr Infect Res, Dept Vaccinol, D-38124 Braunschweig, Germany

[4] Hosp Ninos Dr Ricardo Gutierrez, Serv Parasitol Chagas, Buenos Aires, DF, Argentina

来源：

VACCINE | 2008年 / 26卷 / 16期

关键词：

Chagas disease; Trypanosoma cruzi; MALP-2;

D O I：

10.1016/j.vaccine.2008.02.011

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cruzipain (Cz), a key Tryponosoma cruzi enzyme, is a main candidate antigen for vaccines against Chagas' disease. We evaluated a vaccination protocol based on intradermal priming with recombinant Cz and intranasal, boosting with rCz co-administered with a derivative of the TLR2/6 agonist MALP-2. Vaccination triggered strong systemic and mucosat antibody responses, and a vigorous cell-mediated immunity characterized by lymphoproliferation, DTH reactivity and IFN-gamma production. The immune responses protected against a lethal trypomastigote challenge and, upon sub-Lethal infection, immunized mice showed reduction of tissue damage and normal enzymatic markers of muscle injury. This prime-boost regimen appears promising for further development, since warranted survival, provided efficient control of parasite load and restricted inflammatory myopathy. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1999 / 2009

页数：11

共 42 条

[1] PATHOGENESIS OF CHAGAS-DISEASE [J].